BS_W4DB5RP1
Diffuse intrinsic pontine glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Diffuse intrinsic pontine glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Diffuse intrinsic pontine glioma
- overall_survival_months
- 11.169513797634691
- age_years
- 5.567
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.298
- NOTCH_SIGNALING+0.197
- ESTROGEN_RESPONSE_EARLY+0.176
- G2M_CHECKPOINT+0.166
- WNT_BETA_CATENIN_SIGNALING+0.160
- HEDGEHOG_SIGNALING+0.150
- APICAL_SURFACE+0.148
- TNFA_SIGNALING_VIA_NFKB+0.113
- HYPOXIA+0.110
- MITOTIC_SPINDLE+0.105
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.702
- PROTEIN_SECRETION-0.538
- MYC_TARGETS_V1-0.530
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.522
- DNA_REPAIR-0.475
- ADIPOGENESIS-0.445
- ANDROGEN_RESPONSE-0.372
- FATTY_ACID_METABOLISM-0.369
- MTORC1_SIGNALING-0.342
- ALLOGRAFT_REJECTION-0.337
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_9CA93S6D | Diffuse intrinsic pontine glioma | — | 0.904 |
| 2 | SRR6013482 | — | cohortA1 | 0.882 |
| 3 | BS_97M1E2DW | Diffuse intrinsic pontine glioma | — | 0.847 |
| 4 | MNG790 | — | — | 0.841 |
| 5 | TCGA-56-A5DS-01A-11R-A27Q-07 | — | cohortSQ1 | 0.840 |
| 6 | SRR13311176 | — | — | 0.835 |
| 7 | BS_Q13FQ8FV | Diffuse intrinsic pontine glioma | — | 0.833 |
| 8 | BS_44A3ES23 | Med | Medulloblastoma | 0.825 |
| 9 | SRR6013530 | — | cohortSQ1 | 0.823 |
| 10 | SRR1375271 | GTEX | — | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.298 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.197 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.176 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.166 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.148 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.113 | Inavolisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.105 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.104 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.093 | Inavolisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.046 | Idelalisib | — uncovered |